市場調查報告書
商品編碼
1466113
帶因者篩檢市場:按類型、病理學、技術、最終用戶分類 - 2024-2030 年全球預測Carrier Screening Market by Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), Medical Condition (Hematological Conditions, Neurological Conditions, Pulmonary Conditions), Technology, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年帶因者篩檢市場規模為30.7億美元,預計2024年將達35.2億美元,2030年將達到81.3億美元,複合年成長率為14.93%。
攜帶者篩檢是對個體進行的基因測試,以確定他們是否攜帶特定遺傳疾病的基因。如果您是基因攜帶者,您通常不會表現出該疾病的症狀,但您可以將基因遺傳給有遺傳該疾病風險的後代。特別建議對有遺傳性疾病家族病史的人以及某些遺傳性疾病盛行率較高的某些種族群體的人進行攜帶者篩檢。由於遺傳病患疾病率的增加、潛在父母意識的提高以及旨在減輕遺傳疾病負擔的政府支持政策,攜帶者篩檢的採用正在增加。然而,與遺傳資料、遺傳諮詢的複雜性以及偶爾的誤報/陰性相關的擔憂可能會導致繁瑣的後續測試和即將到來的市場成長。也就是說,次世代定序(NGS)技術的整合可以一次全面篩檢大量遺傳疾病,直接面對消費者的基因檢測服務的潛在成長機會,以及不同地區人群層級的攜帶者篩檢該計畫的擴展預計將為市場成長創造潛在機會。
主要市場統計 | |
---|---|
基準年[2023] | 30.7億美元 |
預測年份 [2024] | 35.2億美元 |
預測年份 [2030] | 81.3億美元 |
複合年成長率(%) | 14.93% |
類型擴展攜帶者篩檢(ECS) 提供遺傳健康和病理狀況的廣泛概況。
擴大帶因者篩檢(ECS)是型態全面的基因檢測,可評估多種遺傳疾病的攜帶者狀況。此類篩檢旨在同時識別罕見和常見遺傳疾病的攜帶者,提供不受血統或家族病史限制的更廣泛的評估。 ECS 經常告知準父母可能影響其後代的遺傳風險。客製化的小組測試允許個人根據個人或家族病史、已知的攜帶者狀態或具體問題選擇他們希望篩檢的特定遺傳疾病。這種量身訂製的方法可確保篩檢適合個人的特定需求和偏好。自訂組合對於不同種族背景的人或懷疑有罕見遺傳疾病在家族中遺傳時特別有用。預設計小組測試是篩檢預先定義的遺傳疾病清單的基因測試。這些小組通常是根據人群中特定疾病的流行情況或根據醫療指南創建的。由於它消除了個體客製化並專注於遺傳專家認為必要的一系列條件,因此它是一種更簡單且可能更具成本效益的攜帶者篩檢選擇。標靶疾病 Thalia篩檢是一種集中篩檢個體是否為特定遺傳疾病帶因者的方法。當已知家庭成員有某種特定疾病的風險或基於種族的指南建議對某種特定疾病篩檢時,通常會進行這種類型的篩檢。
最終使用者:醫院攜帶者篩檢應用的演變
醫院是攜帶者篩檢市場的重要組成部分,提供全面的護理以及廣泛的專家和服務。醫院更喜歡採用最新技術的攜帶者篩檢測試,以獲得準確的結果。這包括次世代定序(NGS) 和基於微陣列的篩檢。醫院選擇攜帶者篩檢來涵蓋廣泛的遺傳疾病,以滿足患者群體的多樣化需求。醫生辦公室和診所主要提供門診護理,並透過攜帶者篩檢提供更個人化的方法。由於預算限制,這些設施優先考慮具有成本效益的解決方案,同時保持基本的品質標準。與大醫院相比,需要更多專業人員的醫生和診所更喜歡簡單易用的攜帶者篩檢套件。由於醫院處理的病例複雜且多樣,因此需要最全面的測試小組和先進的技術。醫生辦公室優先考慮成本和易用性,因為它們很小並且有很多直接的患者互動。
區域洞察
由於意識的提高、技術的進步以及主要市場參與者的存在,美洲是一個成熟的營運商篩檢市場。在美國,人口基因組成的多樣化和醫療保健支出的增加顯著增加了消費者對帶因者篩檢的需求。此外,《平價醫療法案》使更多人能夠進行這些篩檢,對市場產生了正面影響。在這些地區,醫生的建議和消費者基因檢測服務的使用會影響消費者的購買行為。關鍵專利包括用於檢測基因突變的定序技術和生物資訊演算法的進步。歐洲市場的特徵是歐盟國家的消費者需求和購買行為受到文化觀點、醫療保健政策和遺傳諮詢實踐的影響。醫療基礎設施良好、人均收入高的國家,例如斯堪地那維亞國家,攜帶者篩檢的採用率很高。 Horizon Europe 計畫等舉措正在支持該領域的研究和創新,而 GDPR 正在對遺傳資料管理進行立法。近年來,官民合作關係合作的投資旨在增強基因檢測技術。由於近親結婚率高和遺傳病患疾病率高,中東地區對帶因者篩檢的需求不斷增加。中東國家正在投資人口規模的遺傳計劃,以改善公共衛生。在亞太地區,由於醫療基礎設施投資的增加,帶因者篩檢市場正在快速成長。 「健康中國2030」藍圖和「日本基因組」計劃等政府舉措體現了中國對推動基因組醫學的承諾。亞太國家因其新興的中產階級和不斷提高的醫療保健意識而提供了巨大的商機。亞太地區專利重點關注新的基因技術和具有成本效益的測試方法,以滿足不斷成長的市場需求。總體而言,該地區在職業篩檢定位矩陣方面具有巨大的成長和創新潛力。
FPNV定位矩陣
FPNV定位矩陣對於評估帶因者篩檢市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對營運商篩檢市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 帶因者篩檢市場的市場規模和預測是多少?
2.在職業篩檢市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.帶因者篩檢市場的技術趨勢和法規結構是什麼?
4.業者篩檢市場主要廠商的市場佔有率是多少?
5. 進入攜帶者篩檢市場的合適型態和策略手段是什麼?
[183 Pages Report] The Carrier Screening Market size was estimated at USD 3.07 billion in 2023 and expected to reach USD 3.52 billion in 2024, at a CAGR 14.93% to reach USD 8.13 billion by 2030.
Carrier screening is genetic testing conducted on individuals to determine whether they carry a gene for certain genetic disorders. As carriers, these individuals typically do not exhibit symptoms of the disorder; however, they can pass the gene on to their offspring, who may be at risk of inheriting the disease. Carrier screening is particularly recommended for individuals with a family history of genetic disorders or for those within certain ethnic groups that have a higher prevalence of specific genetic conditions. The increasing prevalence of inherited diseases, growing awareness among potential parents, and supportive government policies aimed at reducing the burden of genetic disorders increase the adoption of carrier screening. However, concerns associated with genetic data, the complexity of genetic counseling, and occasional false positives/negatives could lead to cumbersome follow-up testing and impending market growth. Nevertheless, the integration of next-generation sequencing (NGS) technologies, which allow for comprehensive screening of a large number of genetic conditions at once, the potential for growth in direct-to-consumer genetic testing services, and the expansion of carrier screening programs at the population level in various countries are expected to create potential opportunities for the market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.07 billion |
Estimated Year [2024] | USD 3.52 billion |
Forecast Year [2030] | USD 8.13 billion |
CAGR (%) | 14.93% |
Type: Expanded carrier screening (ECS) offers a wide overview of genetic health and conditions
Expanded Carrier Screening (ECS) is a comprehensive form of genetic testing that assesses an individual's carrier status for various genetic disorders, typically including those beyond the recommendations for specific ethnicities. This type of screening is designed to simultaneously identify carriers of rare and common genetic conditions, offering a broader assessment that is not limited by ancestry or family history. ECS often informs prospective parents of potential genetic risks that could affect offspring. Customized panel testing allows individuals to select specific genetic conditions for which they wish to be screened based on personal or family history, known carrier status, or particular concerns. This tailored approach ensures that the screening aligns with the specific needs and preferences of the individual. Custom panels can be particularly beneficial for those with a diverse ethnic background or when a rare genetic disorder is suspected in the family lineage. Predesigned Panel Testing involves genetic tests that screen for a predefined list of genetic disorders. These panels are usually created based on the prevalence of certain conditions within a population or based on medical guidelines. They provide a more straightforward and potentially more cost-effective option for carrier screening, as they omit individual customization and focus on a set of conditions deemed necessary by genetic experts. Targeted disease sarrier screening is a focused approach that screens an individual for the carrier status of a specific genetic disorder. This type of screening is often performed when there is a known risk of a particular condition in a family or by ethnicity-based guidelines recommending screening for certain diseases.
End-User: Evolving application of carrier screening in hospitals
Hospitals represent a critical segment within the carrier screening market, provide comprehensive care, and have access to an expansive range of medical specialists and services. Hospitals prefer carrier screening tests incorporating the latest technologies for accurate results. This includes next-generation sequencing (NGS) and microarray-based screenings. Hospitals opt for carrier screenings that cover a wide range of genetic disorders, fulfilling the diverse needs of their patient population. Physician offices and clinics cater primarily to outpatient care and provide a more personalized approach to carrier screening. Due to budget constraints, these establishments prioritize cost-effective solutions while maintaining basic quality standards. Physicians and clinics that might need more specialized staff of larger hospitals prefer simple, easy-to-use carrier screening kits. Hospitals require the most comprehensive test panels and advanced technologies due to the complexity and variety of cases they handle. Physician offices prioritize cost and user-friendliness, given their smaller scale and more direct patient interactions.
Regional Insights
The Americas have a mature market for carrier screening, owing to heightened awareness, technological advancements, and the presence of key market players. In the United States, there is a considerable consumer need for carrier screening due to the diverse genetic makeup of the population and increasing healthcare expenditure. The Affordable Care Act has also impacted the market positively by enabling a broader population to access such screenings. Physician recommendations and the availability of direct-to-consumer genetic testing services influence customer purchasing behavior in these regions. Key patents include advances in sequencing technologies and bioinformatics algorithms for detecting genetic variants. The European market is characterized by consumer needs and purchasing behavior across EU countries, shaped by cultural perspectives, healthcare policies, and genetic counseling practices. Nations with more robust healthcare infrastructure and higher per capita income, such as the Scandinavian countries, exhibit higher adoption rates of carrier screening. Initiatives, including the Horizon Europe program, support research and innovation in the field while GDPR legislates genetic data management. Recent investments are seen in public-private partnerships aimed at enhancing genetic testing technologies. The Middle East is experiencing an increase in demand for carrier screening due to high consanguinity rates, leading to a greater prevalence of genetic disorders. Countries in the Middle East are investing in population-scale genetic projects to improve public health. In Asia-Pacific, carrier screening markets are experiencing rapid growth due to increased investment in healthcare infrastructure. Government initiatives such as the "Healthy China 2030" blueprint and the "Genome Japan" project reflect the country's commitment to advancing genomic medicine. Countries in Asia-Pacific present a vast opportunity, with a burgeoning middle class and increasing healthcare awareness. Patents in the Asia Pacific region are focusing on new genetic technologies and cost-effective testing methods to cater to the growing market. Overall, the region presents a significant potential for growth and innovation in carrier screening.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Carrier Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Carrier Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Carrier Screening Market, highlighting leading vendors and their innovative profiles. These include 23Andme Inc., Abbott Laboratories, Ambry Genetics Corporation by Konica Minolta, Inc., Asper Biogene, Autogenomics Inc. by Prescient Medicine Holdings Inc., BGI Genomics Co., Ltd., Biora Therapeutics, Inc., CENTOGENE N.V., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Gene by Gene, Ltd. by myDNA Inc., GeneDx Holdings Corp., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation by DiaSorin Company, MedGenome Labs Ltd., Myriad Genetics, Inc., Natera, Inc., OPKO Health, Inc., Otogenetics Corporation, Quest Diagnostics Inc., Thermo Fisher Scientific Inc., and TRUE HEALTH LABS.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Carrier Screening Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Carrier Screening Market?
3. What are the technology trends and regulatory frameworks in the Carrier Screening Market?
4. What is the market share of the leading vendors in the Carrier Screening Market?
5. Which modes and strategic moves are suitable for entering the Carrier Screening Market?
TABLE